Want to see PYXS full AI Analyst Report?

Pyxis Oncology (PYXS) Price & Analysis

647 Followers

PYXS Stock Chart & Stats

$2.61

$0.30(11.49%)

At close: Jul 27 4:00 PM EDT

$2.61

$0.30(11.49%)

Day’s Range― - ―

52-Week Range$0.97 - $5.55

Previous CloseN/A

Volume197.33K

Average Volume (3M)757.02K

Market Cap

$167.89M

Enterprise Value$68.43

Total Cash (Recent Filing)$42.49M

Total Debt (Recent Filing)$18.26M

Price to Earnings (P/E)―

Beta1.41

Next Earnings

Aug 19, 2026

EPS Estimate

-0.35

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.31

Shares Outstanding63,355,480

10 Day Avg. Volume789,983

30 Day Avg. Volume757,017

Financial Highlights & Ratios

PEG Ratio0.30

Price to Book (P/B)1.34

Price to Sales (P/S)5.16

P/FCF Ratio-1.13

Enterprise Value/Market Cap<0.01

Enterprise Value/Revenue<0.01

Enterprise Value/Gross Profit<0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$7.29

Price Target Upside179.15% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

EPS Forecast (FY)-1.22

Revenue Forecast (FY)$66.67K

Bulls Say, Bears Say

Bulls Say

Extended Cash Runway From Private PlacementThe ~$50M upfront financing (with up to $64M via warrants) extends cash runway into Q2 2027, enabling continued clinical development and planned MICVO readouts. This reduces immediate fundraising pressure and allows management to prioritize data generation over urgent capital raises for the next 8–12 months.

Focused Antibody/ADC Immuno-oncology PipelinePyxis's strategy centers on antibody therapeutics and ADCs in immuno-oncology, a structural growth area with high unmet need. A focused clinical-stage portfolio concentrates resources on a few programs (eg, MICVO), creating clear milestone-driven value inflection opportunities if mid-stage data validate mechanisms.

Strengthened Governance And Audit OversightApproval of directors and Ernst & Young as auditor reinforces board continuity and independent financial oversight. Strong governance and credible external audit support disciplined capital allocation and reliable reporting, which matter for sponsor/partner diligence and long-term strategic execution in clinical-stage biotech.

Bears Say

High And Persistent Cash BurnSustained TTM operating and free cash flow near -$67M demonstrates chronic cash consumption tied to R&D and trials. Ongoing negative cash generation necessitates recurring financings, elevates dilution risk, and constrains the company's ability to advance multiple programs or scale operations without external capital or partnering.

Shrinking Equity Base And Contracted AssetsA sharp contraction in shareholders' equity and total assets reduces the balance-sheet buffer available for setbacks. Lower book equity limits financial flexibility, increases reliance on markets or partners for funding, and heightens vulnerability to trial delays, unexpected costs, or adverse data.

Revenue Decline And Non-recurring MixReported revenue (~$13.9M TTM) dropped versus prior year and is described as driven by one-off licensing/milestone items. Lack of recurring commercial revenue means the company cannot self-fund development long-term, making progress heavily dependent on successful clinical outcomes or partner deals to create sustainable cash flow.

Pyxis Oncology News

Pyxis Oncology initiated with an Overweight at Wells Fargo

Wells Fargo initiated coverage of Pyxis Oncology (PYXS) with an Overweight rating and $12 price target The firm...

3d ago

PYXS

Pyxis Oncology Raises Capital Through Private Placement Financing

The latest announcement is out from Pyxis Oncology ( ($PYXS) ). Pyxis Oncology entered into definitive securities purchase...

1M ago

PYXS

Pyxis Oncology announces up to $114M private placement

Pyxis Oncology (PYXS) announced that it has entered into definitive securities purchase agreements for a private placement expected...

1M ago

PYXS

Pyxis Oncology Stockholders Approve Directors and Auditor Slate

Pyxis Oncology ( ($PYXS) ) has shared an announcement. On June 15, 2026, Pyxis Oncology, Inc. held its...

2M ago

PYXS

Pyxis Oncology Faces Urgent Capital Needs and Potential Dilution Risks Amid Market Volatility

Pyxis Oncology, Inc. (PYXS) has disclosed a new risk, in the Debt & Financing category. Pyxis Oncology, Inc....

3M ago

PYXS

Pyxis Oncologyreports Q1 EPS (37c), consensus (35c)

“Our team’s exceptional clinical and operational execution in the first quarter of 2026, combined with growing investigator enthusiasm...

3M ago

PYXS

PYXS Earnings this Week: How Will it Perform?

Pyxis Oncology, Inc. (PYXS) is scheduled to report 1st quarter earnings on 05/08/2026. Regarding Q1 estimates, Wall Street...

3M ago

PYXS

Wedbush bullish on Pyxis Oncology, initiates with an Outperform

As previously reported, Wedbush analyst Robert Driscoll initiated coverage of Pyxis Oncology (PYXS) with an Outperform rating and...

3M ago

PYXS

Pyxis Oncology initiated with an Outperform at Wedbush

Wedbush initiated coverage of Pyxis Oncology (PYXS) with an Outperform rating and $6 price target Published first on...

3M ago

PYXS

Pyxis Oncology price target lowered to $8 from $9 at Stifel

Stifel lowered the firm’s price target on Pyxis Oncology (PYXS) to $8 from $9 and keeps a Buy...

4M ago

PYXS

Pyxis Oncology Reports Q4 Results, Advances MICVO Program

The latest announcement is out from Pyxis Oncology ( ($PYXS) ). Pyxis Oncology reported a series of clinical...

5M ago

PYXS

PYXS Earnings this Week: How Will it Perform?

Pyxis Oncology, Inc. (PYXS) is scheduled to report 4th quarter earnings on 03/25/2026. Regarding Q4 estimates, Wall Street...

5M ago

PYXS

Pyxis Oncology Announces Interim CEO Amid Leadership Transition

Pyxis Oncology ( ($PYXS) ) has shared an update. On February 2, 2026, Pyxis Oncology implemented a leadership...

6M ago

PYXS

Pyxis Oncology appoints board member Thomas Civik as Interim CEO

Pyxis Oncology (PYXS) announced a leadership transition. Thomas Civik, a member of Pyxis Oncology’s Board of Directors since...

6M ago

PYXS

PYXS FAQ

What was Pyxis Oncology’s price range in the past 12 months?

Pyxis Oncology lowest stock price was $0.97 and its highest was $5.55 in the past 12 months.

What is Pyxis Oncology’s market cap?

Pyxis Oncology’s market cap is $167.89M.

When is Pyxis Oncology’s upcoming earnings report date?

Pyxis Oncology’s upcoming earnings report date is Aug 19, 2026 which is in 13 days.

How were Pyxis Oncology’s earnings last quarter?

Pyxis Oncology released its earnings results on May 14, 2026. The company reported -$0.37 earnings per share for the quarter, missing the consensus estimate of -$0.364 by -$0.006.

Is Pyxis Oncology overvalued?

According to Wall Street analysts Pyxis Oncology’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Pyxis Oncology pay dividends?

Pyxis Oncology does not currently pay dividends.

What is Pyxis Oncology’s EPS estimate?

Pyxis Oncology’s EPS estimate is -0.35.

How many shares outstanding does Pyxis Oncology have?

Pyxis Oncology has 63,355,480 shares outstanding.

What happened to Pyxis Oncology’s price movement after its last earnings report?

Pyxis Oncology reported an EPS of -$0.37 in its last earnings report, missing expectations of -$0.364. Following the earnings report the stock price went down -15.649%.

Which hedge fund is a major shareholder of Pyxis Oncology?

Currently, no hedge funds are holding shares in PYXS

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Pyxis Oncology Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-52.67%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Pyxis Oncology

Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being explored for its potential efficacy against thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors. Additionally, PYX-102 is an immune-therapeutic currently under investigation for the treatment of solid tumors. The company's portfolio also features a range of investigational antibody-drug conjugate (ADC) candidates: PYX-201, a novel ADC being developed for NSCLC, breast cancer, and other solid tumors; PYX-202, another novel ADC aimed at small cell lung cancer (SCLC), soft tissue sarcoma, and other solid tumors; and PYX-203, an ADC undergoing evaluation for acute myeloid leukemia and myeloid dysplastic syndrome. Pyxis Oncology was founded in 2018 and is based in Cambridge, Massachusetts.

Pyxis Oncology (PYXS) Earnings & Revenues

Historic Earnings Reports

PYXS Stock 12 Month Forecast

Average Price Target

$7.29

▲(179.15% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7.285714285714286,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$7.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$5.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.65,3.3692307692307693,4.088461538461538,4.8076923076923075,5.526923076923077,6.246153846153846,6.965384615384615,7.684615384615384,8.403846153846153,9.123076923076923,9.842307692307692,10.561538461538461,11.28076923076923,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.65,3.0065934065934066,3.3631868131868132,3.71978021978022,4.076373626373626,4.432967032967033,4.789560439560439,5.146153846153846,5.502747252747253,5.85934065934066,6.215934065934066,6.572527472527472,6.9291208791208785,{"y":7.285714285714286,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.65,2.8307692307692305,3.0115384615384615,3.192307692307692,3.373076923076923,3.5538461538461537,3.7346153846153847,3.9153846153846152,4.096153846153846,4.276923076923077,4.457692307692308,4.638461538461538,4.819230769230769,{"y":5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.1,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.33,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.39,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.15,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.53,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.47,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.79,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.85,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.65,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >